ACADIA Pharmaceuticals Inc
(NAS:ACAD)
$
16.95
-0.42 (-2.42%)
Market Cap: 2.89 Bil
Enterprise Value: 2.37 Bil
PE Ratio: 22.27
PB Ratio: 5.01
GF Score: 75/100 ACADIA Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) - Panel: Emerging Therapies for Psychiatric Disorders Transcript
Sep 09, 2020 / 05:30PM GMT
Release Date Price:
$37.9
(-0.79%)
Neena Marie Bitritto;Garg
Citigroup Inc. Exchange Research - Research Analyst
I think we're live, right, now?
Joel Lawrence Beatty
Citigroup Inc., Research Division - VP & Analyst
Yes.
Neena Marie Bitritto;Garg
Citigroup Inc. Exchange Research - Research Analyst
Okay. Oh hi, everyone. Thank you so much for joining the Citi 15th Annual Biopharma Conference. My name is Neena Bitritto-Garg. I am one of the smid-cap biotech analysts here at Citi. So I am very pleased to have with us today management teams from ACADIA. So we have Serge from ACADIA. We have also management teams from Minerva Neurosciences and from Karuna as well. And I'm also joined by my colleagues, Joel Beatty and Mohit, if they want to give some introductory remarks to introduce their management teams as well.
Mohit Bansal
Citigroup Inc., Research Division - Director and Analyst
Great. I mean, from my side, I mean, we have Steve Paul, the CEO of Karuna with us, and
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot